BioSpace News Archive

IRADIMED CORPORATION announced today its common stock will uplist and commence trading on the Nasdaq Global Market, effective June 14, 2024, and will continue under the ticker symbol “IRMD.”

Vistagen today announced it will host a conference call and webcast on Tuesday, June 11, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 ended March 31, 2024 and provide a corporate update.

ChromaDex Corp. today announced that the U.S. Food & Drug Administration (FDA) granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for NRC, the company’s product candidate for the treatment of Ataxia Telangiectasia (AT).

Asensus Surgical, Inc. today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with KARL STORZ Endoscopy-America, Inc.

The Board of Directors of AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a land-based aquaculture company utilizing technology to enhance productivity and sustainability

Helix , the leading population genomics company, is launching new clinico-genomic datasets to enable life science companies to drive precision medicine drug discovery and development.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:.

Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 80,000 shares of its common stock with an exercise price of $0.71 per share, which is equal to the closing price of Kezar’s common stock on June 3, 2024, the grant date of the award.

GSK plc announced that the US Food and Drug Administration has approved AREXVY Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease in adults 50 through 59 years of age who are at increased risk.